Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
September 06 2023 - 9:20AM
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)
(“Clearmind” or the "company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, is pleased to
announce that the company has entered into a Clinical Trial
Agreement with Johns Hopkins University School of Medicine (“JHU”)
to conduct its Phase I/IIa clinical trial of its proprietary
MEAI-based CMND-100 (“
CMND-100”).
The principal investigator, Jennifer Ellis, PhD, Associate
Professor of Psychiatry and Behavioral Sciences, JHU School of
Medicine will be supported by co-investigators Professor Eric
Strain, Director, Behavioral Pharmacology Research Unit, JHU School
of Medicine.
"We are honored to collaborate with JHU for our first in human
clinical trial. JHU is one of the global leaders in psychedelics
clinical research and in researching addictions, and we are very
grateful to partner with them to study our proprietary CMND-100 to
treat Alcohol Use Disorder," said Clearmind’s Chief Executive
Officer Dr. Adi Zuloff-Shani. "Johns Hopkins is our second US
clinical site joining our trial, following Yale School of
Medicine’s Department of Psychiatry. We are excited to be working
closely with two of the world’s leading medical centers, who have
researched our treatment and agreed to participate in our clinical
program."
The potential of psychedelic drugs to treat various
neuropsychiatric indications is currently being explored in several
human clinical trials. Clearmind’s phase I/IIa trial, CM-CMND-001,
the primary end point of the clinical trial is to find the
tolerable dose and characterize the safety and
pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated
doses of CMND-100 in healthy subjects and those with Alcohol
Use Disorder ("AUD"). The secondary end point is to evaluate
the efficacy of CMND-100 in reduction of drinking patterns and
cravings, in individuals with moderate-to-severe AUD. Oral capsules
will be administered once daily, for ten consecutive days. The
patients will report their drinking patterns and craving for
alcohol (and cigarettes) during the clinical trial period.
CM-CMND-001 clinical trial is a multinational, multi-center,
Phase I/II single- and multiple-dose tolerability, safety and
pharmacokinetic study in healthy volunteers and AUD subjects.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
fourteen patent families. The Company intends to seek additional
patents for its compounds whenever warranted and will remain
opportunistic regarding the acquisition of additional intellectual
property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the
Canadian Securities Exchange under the symbol "CMND" and the
Frankfurt Stock Exchange under the symbol “CWY.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relations invest@clearmindmedicine.com Telephone: (604)
260-1566 US: CMND@crescendo-ir.com
General Inquiries Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses potential future
collaboration with CTS. Forward-looking statements are not
historical facts, and are based upon management’s current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual performance or results to
differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and
uncertainties affecting the Company, reference is made to the
Company’s reports filed from time to time with the Securities and
Exchange Commission (“SEC”), including, but not limited to, the
risks detailed in the Company’s annual report on Form 20-F filed
with the SEC on February 6, 2023. Forward-looking statements speak
only as of the date the statements are made. The Company assumes no
obligation to update forward-looking statements to reflect actual
results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information
except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no
inference should be drawn that the Company will make additional
updates with respect thereto or with respect to other
forward-looking statements. References and links to websites have
been provided as a convenience, and the information contained on
such websites is not incorporated by reference into this press
release. Clearmind is not responsible for the contents of
third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Apr 2024 to May 2024
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From May 2023 to May 2024